镓-68前列腺特异性膜抗原靶向正电子发射断层扫描分期的去势敏感寡转移性前列腺癌局部消融图像引导放疗的毒性与疗效:OLI-P 2期临床试验
OLI-P是一项在德国两个中心开展的非随机、前瞻性、研究者发起的2期试验,纳入2014至2018年局部治愈性治疗后、无显著合并症且未接受雄激素剥夺治疗的寡转移性前列腺癌患者(≤5个淋巴结或骨转移灶),所有PSMA-PET阳性转移灶接受局部消融放疗,主要终点为放疗后24个月治疗相关毒性(≥2级)。72例中63例接受放疗(脱落率13%),中位随访37.2个月,2年后未观察到治疗相关≥2级毒性,至PSA进展和至ADT的中位时间分别为13.2和20.6个月,21.4%的患者3年后无PSA进展。
要点
- 放疗后2年未观察到治疗相关≥2级毒性,中位随访37.2个月。
- 至PSA进展和至ADT的中位时间分别为13.2和20.6个月。
- 21.4%的患者3年后无PSA进展,约五分之一患者中期无ADT。
核心结论
- 观察到局部消融放疗是安全的,约五分之一患者获得中期PSA进展控制和免ADT时间。
- 作者认为需要随机临床试验进一步评估在选定患者中延迟ADT的选项。
研究设计与样本
- 非随机、前瞻性、研究者发起的2期试验,在德国两个中心于2014至2018年招募患者。
- 纳入局部治愈性治疗后、无显著合并症且未接受ADT的寡转移性前列腺癌患者(≤5个淋巴结或骨转移灶)。
- 所有PSMA-PET阳性转移灶接受局部消融放疗,未启动全身治疗。
- 72例患者中63例接受放疗,脱落率13%。
- 主要终点为放疗后24个月治疗相关毒性(≥2级),计划采用单侧单样本比例检验判断终点发生率是否<15%。
主要发现
- 中位随访37.2个月,治疗2年后未观察到治疗相关≥2级毒性。
- 至PSA进展的中位时间为13.2个月,至ADT的中位时间为20.6个月。
- 21.4%的患者3年后无PSA进展。
关键数值与推荐
- 主要终点计划检验治疗相关≥2级毒性发生率是否<15%。
- 至PSA进展和至ADT的中位时间分别为13.2和20.6个月。
- 3年无PSA进展率为21.4%。
临床怎么用
- 作者认为局部消融放疗可能是选定患者中避免全身治疗的一种选择。
- 作者认为需要随机临床试验进一步评估在选定患者中延迟ADT的选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research. OBJECTIVE: We hypothesize that aRT is safe and effective in gallium-68 prostate-specific membrane antigen targeted positron emission tomography (PSMA-PET)-staged oligometastatic PCa patients. DESIGN, SETTING, AND PARTICIPANTS: A nonrandomized, prospective, investigator-initiated phase 2 trial recruited patients with oligometastatic PCa (five or fewer lymph node or osseous metastases) after local curative therapy, without significant comorbidity and androgen deprivation therapy (ADT), at two German centers from 2014 to 2018. INTERVENTION: All PSMA-PET-positive metastases were treated with aRT. No systemic therapy was initiated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was treatment-related toxicity (grade ≥2) 24 mo after aRT. A one-sided single-sample test of proportions was planned to test whether the endpoint occurs in <15% of the patients. Key secondary endpoints were time to progression of prostate-specific antigen (PSA) and time to ADT, which were associated with potential prognostic factors by Cox regression. RESULTS AND LIMITATIONS: Of 72 patients, 63 received aRT (13% dropout rate). The median follow-up was 37.2 mo. No treatment-related grade ≥2 toxicity was observed 2 yr after treatment. The median time to PSA progression and time to ADT were 13.2 and 20.6 mo, respectively. Of the patients, 21.4% were free of PSA progression after 3 yr. CONCLUSIONS: It was observed that aRT is safe, and midterm PSA progression and ADT-free time were achieved in one of five patients. Randomized clinical trials are indicated to further evaluate the option of delaying ADT in selected patients. PATIENT SUMMARY: In this clinical trial, 63 patients with up to five metastases of prostate cancer without androgen deprivation therapy were included. We showed that local ablative radiotherapy is safe and that one in five patients had no recurrent prostate-specific antigen value after 3 yr. Local ablative radiotherapy might be an option to avoid systemic therapy in selected patients.
引用
- Hölscher T, Baumann M, Kotzerke J, et al. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. Eur Urol Oncol. 2021. PMID: 34785189. doi:10.1016/j.euo.2021.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。